A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

NCT04414475 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma, Refractory

Interventions

DRUG: Selinexor
DRUG: Dexamethasone
DRUG: Bortezomib

Sponsor

Karyopharm Therapeutics Inc